Body fat in men with prolactinoma

Journal of Endocrinological Investigation

Volumn 31, Issue 11, 2008, Pages 985-990

  Naliato, Erika C O ^a,e   Violante, A H D ^a   Gaccione, M ^b   Caldas, D ^c   Filho, A Lamounier ^a   Loureiro, C R ^a   Fontes, R ^d   Schrank, Y ^d   Costa, F S R ^a   Colao, A ^b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c Instituto Estadual de Diabetes e Endocrinologia Luiz Capriglione   (Brazil)

^d Diagnósticos da America S A   (Brazil)

^e UFRJ ^*  (Brazil)

Author keywords

Body composition; Hyperprolactinemia; Men; Prolactinoma

Indexed keywords

ANDROSTANOLONE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; ESTRADIOL; PROLACTIN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; ANTHROPOMETRY; ARTICLE; BODY FAT; BODY FAT DISTRIBUTION; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTRADIOL BLOOD LEVEL; HUMAN; HYPOPHYSECTOMY; MALE; OBESITY; PROLACTIN BLOOD LEVEL; PROLACTINOMA; PROTEIN BLOOD LEVEL; TESTOSTERONE BLOOD LEVEL;

EID: 59849123900     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03345636     Document Type: Article

References (29)

1. Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev 2006, 27: 485-534.
2. Colao A, Vitale G, Cappabianca P, et al. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab 2004, 89: 1704-11.
3. Naliato ECO, Farias MLF, Braucks GR, Costa FSR, Zylberberg D, Violante AHD. Prevalence of osteopenia in men with prolactinoma. J Endocrinol Invest 2005, 28: 12-7.
4. Buntin JD, Hnasko RM, Zuzick PH. Role of ventromedial hypothalamus in prolactin-induced hyperphagia in ring doves. Physiol Behav 1999, 66: 255-61.
5. Sauvé D, Woodside B. The effect of central administration of prolactin on food intake in virgin female rats is dose-dependent, occurs in the absence of ovarian hormones and the latency to onset varies with feeding regimen. Brain Res 1996, 729: 75-81.
6. Freemark M, Fleenor D, Driscoll P, Binart N, Kelly PA. Body weight and fat deposition in prolactin receptor-deficient mice. Endocrinology 2001, 142: 532-7.
7. Ling C, Svensson L, Odén B, et al. Identification of functional prolactin (PRL) receptor gene expression: PRL inhibits lipoprotein lipase activity in human white adipose tissue. J Clin Endocrinol Metab 2003, 88: 1804-8.
8. Colao A, Sarno AD, Cappabianca P, et al. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 2003, 148: 325-31.
9. Greenman Y, Tordjman K, Stern N. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin Endocrinol (Oxf) 1998, 48: 547-53.
10. Gualillo O, Lago F, García M, et al. Prolactin stimulates leptin secretion by rat white adipose tissue. Endocrinology 1999, 140: 5149-53.
11. Watanobe H, Suda T, Wikberg JE, Schiöth HB. Evidence that physiological levels of circulating leptin exert stimulatory effect on luteinizing hormone and prolactin surges in rats. Biochem Biophys Res Commun 1999, 263: 162-5.
12. Kok P, Roelfsema F, Frölich M, Meinders AE, Pijl H. Prolactin release is enhanced in proportion to excess visceral fat in obese women. J Clin Endocrinol Metab 2004, 89: 4445-9.
13. Doknic M, Pekic S, Zarkovic M, et al. Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Eur J Endocrinol 2002, 147: 77-84.
14. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab 2004, 89: 2583-9.
15. Kreisberg RA, Oberman A. Lipids and atherosclerosis: Lessons learned from randomized controlled trials of lipid lowering and other relevant studies. J Clin Endocrinol Metab 2002, 87: 423-37.
16. Molitch ME. Prolactin. In: S. Melmed ed. The pituitary, 2nd ed. Malden, Massachusetts, USA: Blackwell Publishing. 2002, 119-71.
17. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 2004, 89: 2595-600.
18. Abate N, Haffner SM, Garg A, Peshock RM, Grundy SM. Sex steroid hormones, upper body obesity, and insulin resistance. J Clin Endocrinol Metab 2002, 87: 4522-7.
19. Schneider HJ, Glaesmer H, Klotsche J, et al. Waist-to-tallness ratio (WTR) is the best anthropometric indicator of cardiovascular risk-Findings from the DETECT Study. Program of the 87th Annual Meeting of the Endocrine Society. 2005, P1-714.
20. Pinzone JJ, Katznelson L, Danila DC, Pauler DK, Miller CS, Klibanski A. Primary medical therapy of micro- and macroprolactinomas in men. J Clin Endocrinol Metab 2000, 85: 3053-7.
21. Berezin M, Shimon I, Hadani M. Prolactinoma in 53 men: clinical characteristics and modes of treatment (male prolactinoma). J Endocrinol Invest 1995, 18: 436-41.
22. Braucks GR, Naliato ECO, Tabet ALO, Gadelha MR, Violante AHD. Clinical and therapeutic aspects of prolactinoma in men. Arq Neuropsiquiatr 2003, 61: 1004-10.
23. Naliato ECO, Violante AHD, Caldas D, et al. Body fat in nonobese women with prolactinoma treated with dopamine agonists. Clin Endocrinol (Oxf) 2007, 67: 845-52.
24. Smith JC, Bennett S, Evans LM, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 2001, 86: 4261-7.
25. Brodsky IG, Balagopal P, Nair KS. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men - a clinical research center study. J Clin Endocrinol Metab 1996, 81: 3469-75.
26. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 1999, 84: 2647-53.
27. Schroeder ET, Zheng L, Ong MD, et al. Effects of androgen therapy on adipose tissue and metabolism in older men. J Clin Endocrinol Metab 2004, 89: 4863-72.
28. Sih R, Morley JE, Kaiser FE, Perry HM 3rd, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 1997, 82: 1661-7.
29. Chrisoulidou A, Beshyah SA, Rutherford O, et al. Effects of 7 years of growth hormone replacement therapy in hypopituitary adults. J Clin Endocrinol Metab 2000, 85: 3762-9.